April 25th 2024
The company adds a top-10 CDMO to its portfolio in the process, while also expanding its commitment to the pharma industry.
Roche Pulls Out of Agreement With Repare Therapeutics to Develop Novel Cancer Therapy
February 13th 2024Roche and Repare came to terms on a deal in June 2022 to develop and commercialize camonsertib, which included a $125 million upfront payment and could have reached up to $1.2 billion based on clinical, regulatory, commercial, and sales milestones.